Huntington National Bank Increases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Huntington National Bank increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 97.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 573 shares of the company’s stock after acquiring an additional 283 shares during the quarter. Huntington National Bank’s holdings in Krystal Biotech were worth $104,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech during the second quarter valued at about $28,000. Key Financial Inc purchased a new position in Krystal Biotech during the second quarter worth about $28,000. Blue Trust Inc. grew its position in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KRYS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $197.00.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $170.74 on Monday. The stock has a market capitalization of $4.91 billion, a P/E ratio of 96.46 and a beta of 0.82. Krystal Biotech, Inc. has a 52-week low of $96.73 and a 52-week high of $219.34. The stock’s 50-day simple moving average is $180.83 and its 200 day simple moving average is $181.64.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter in the previous year, the firm posted ($0.67) EPS. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. Equities research analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).